Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

8.41
+1.1215.32%
Volume:2.67M
Turnover:20.98M
Market Cap:870.23M
PE:-1.60
High:8.41
Open:7.88
Low:7.24
Close:7.29
Loading ...

Intellia Therapeutics Inc : Wells Fargo Cuts Target Price to $70 From $80

THOMSON REUTERS
·
18 Nov 2024

Evercore ISI Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
18 Nov 2024

TD Cowen Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
18 Nov 2024

Truist Financial Releases a Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
18 Nov 2024

Intellia Therapeutics Shares up 13.9% Premarket on Promising Early-Stage Data of Experimental Gene Therapy for Rare Disease

THOMSON REUTERS
·
18 Nov 2024

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

TIPRANKS
·
18 Nov 2024

Intellia Therapeutics price target raised to $91 from $88 at Chardan

TIPRANKS
·
18 Nov 2024

Intellia Therapeutics: Promising Early Trial Results for nex-z, But Hold Rating Due to Uncertainty in Competitive Gene Editing Landscape

TIPRANKS
·
18 Nov 2024

Stock Track | Intellia Therapeutics Soars 16% Pre-Market on Promising Drug Data, Bullish Analyst Outlook

Stock Track
·
18 Nov 2024

Stock Track | Intellia Therapeutics Soars 18.11% on Promising Drug Data, Bullish Analyst Rating

Stock Track
·
18 Nov 2024

Intellia Therapeutics: Buy Rating Driven by Promising Efficacy and Safety of Nex-Z Treatment

TIPRANKS
·
18 Nov 2024

Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-Z), an in Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (Attr) Amyloidosis

THOMSON REUTERS
·
16 Nov 2024

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswire
·
16 Nov 2024

Intellia Therapeutics (NTLA) Gets a Buy from Truist Financial

TIPRANKS
·
11 Nov 2024

Stock Track | Intellia Therapeutics Soars on Bullish Analyst Sentiment

Stock Track
·
11 Nov 2024

Intellia Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
11 Nov 2024

Intellia Therapeutics Inc : Truist Securities Cuts Target Price to $90 From $120

THOMSON REUTERS
·
11 Nov 2024

Truist Securities Cuts Price Target on Intellia Therapeutics to $90 From $120, Maintains Buy Rating

MT Newswires Live
·
11 Nov 2024

Analysts Are Bullish on These Healthcare Stocks: Cullinan Management (CGEM), Intellia Therapeutics (NTLA)

TIPRANKS
·
11 Nov 2024

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Veeva Systems (VEEV) and Neuren Pharmaceuticals Limited (OtherNURPF)

TIPRANKS
·
11 Nov 2024